72 related articles for article (PubMed ID: 8951355)
21. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
Kahn D; Austin JC; Maguire RT; Miller SJ; Gerstbrein J; Williams RD
Cancer Biother Radiopharm; 1999 Apr; 14(2):99-111. PubMed ID: 10850293
[TBL] [Abstract][Full Text] [Related]
25. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Herrada J; Dieringer P; Logothetis CJ
J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
[TBL] [Abstract][Full Text] [Related]
26. [Reliability of CT for determining lymphatic involvement in patients with prostate cancer].
Amo FH; Verdú Tartajo F; Díez Cordero JM; Lledó García E; Bueno Chomón G; Leal Hernández F
Arch Esp Urol; 1997 Jun; 50(5):464-8. PubMed ID: 9382588
[TBL] [Abstract][Full Text] [Related]
27. Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
Berruti A; Dogliotti L; Fasolis G; Mosca A; Tarabuzzi R; Torta M; Mari M; Fontana D; Angeli A
J Urol; 1999 Jan; 161(1):176-81. PubMed ID: 10037393
[TBL] [Abstract][Full Text] [Related]
28. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
[TBL] [Abstract][Full Text] [Related]
29. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
Huan SD; Natale RB; Stewart DJ; Sartiano GP; Stella PJ; Roberts JD; Symes AL; Finizio M
Clin Cancer Res; 2000 Apr; 6(4):1333-6. PubMed ID: 10778959
[TBL] [Abstract][Full Text] [Related]
30. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?
Zagars GK; Kavadi VS; Pollack A; von Eschenbach AC; Sands ME
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):21-32. PubMed ID: 7536722
[TBL] [Abstract][Full Text] [Related]
31. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.
Oefelein MG; Agarwal PK; Resnick MI
J Urol; 2004 Apr; 171(4):1525-8. PubMed ID: 15017212
[TBL] [Abstract][Full Text] [Related]
32. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
33. Atypical metastases from prostate cancer: 10-year experience at a single institution.
Vinjamoori AH; Jagannathan JP; Shinagare AB; Taplin ME; Oh WK; Van den Abbeele AD; Ramaiya NH
AJR Am J Roentgenol; 2012 Aug; 199(2):367-72. PubMed ID: 22826398
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer abdominal metastases detected with indium-111 capromab pendetide.
Hinkle GH; Burgers JK; Olsen JO; Williams BS; Lamatrice RA; Barth RF; Rogers B; Maguire RT
J Nucl Med; 1998 Apr; 39(4):650-2. PubMed ID: 9544673
[TBL] [Abstract][Full Text] [Related]
35. Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma.
Schmid HP; Morant R; Bernhard J; Maibach R;
Eur Urol; 2003 Jan; 43(1):28-30. PubMed ID: 12507540
[TBL] [Abstract][Full Text] [Related]
36. Mesenteric adenopathy in patients with prostate cancer: frequency and etiology.
Coakley FV; Lin RY; Schwartz LH; Panicek DM
AJR Am J Roentgenol; 2002 Jan; 178(1):125-7. PubMed ID: 11756105
[TBL] [Abstract][Full Text] [Related]
37. [The relationship between serum prostate-specific antigen and the skeletal- and CT-scan in staging of primary prostate cancer].
Jager GJ
Ned Tijdschr Geneeskd; 1998 Oct; 142(40):2218. PubMed ID: 9864495
[No Abstract] [Full Text] [Related]
38. [Metastatic cáncer presentation. Validation of a diagnostic algorithm with 221 consecutive patients].
Losa Gaspà F; Germá JR; Albareda JM; Fernández-Ortega A; Sanjosé S; Fernández Trigo V
Rev Clin Esp; 2002 Jun; 202(6):313-9. PubMed ID: 12093395
[TBL] [Abstract][Full Text] [Related]
39. PSA following irradiation for prostate cancer: the upcoming ASTRO symposium.
Shipley WU
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):1115. PubMed ID: 8751422
[No Abstract] [Full Text] [Related]
40. The role of staging CT scans in the treatment of prostate cancer: a retrospective audit.
Burcombe RJ; Ostler PJ; Ayoub AW; Hoskin PJ
Clin Oncol (R Coll Radiol); 2000; 12(1):32-5. PubMed ID: 10749017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
